CY1118231T1 - Συνθεση λιποσωματος - Google Patents

Συνθεση λιποσωματος

Info

Publication number
CY1118231T1
CY1118231T1 CY20161100911T CY161100911T CY1118231T1 CY 1118231 T1 CY1118231 T1 CY 1118231T1 CY 20161100911 T CY20161100911 T CY 20161100911T CY 161100911 T CY161100911 T CY 161100911T CY 1118231 T1 CY1118231 T1 CY 1118231T1
Authority
CY
Cyprus
Prior art keywords
liposome
composition
erivulin
preparation
provides
Prior art date
Application number
CY20161100911T
Other languages
English (en)
Inventor
Hiroshi Kikuchi
Kenji Hyodo
Hiroshi Ishihara
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42828273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118231(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CY1118231T1 publication Critical patent/CY1118231T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια νέα σύνθεση λιποσώματος που περιέχει εριβουλίνη ή το φαρμακολογικά επιτρεπόμενο άλας της, και την μέθοδο παρασκευής της.
CY20161100911T 2009-03-30 2016-09-14 Συνθεση λιποσωματος CY1118231T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16465309P 2009-03-30 2009-03-30
JP2009082521 2009-03-30
PCT/JP2010/055770 WO2010113984A1 (ja) 2009-03-30 2010-03-30 リポソーム組成物

Publications (1)

Publication Number Publication Date
CY1118231T1 true CY1118231T1 (el) 2017-06-28

Family

ID=42828273

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100911T CY1118231T1 (el) 2009-03-30 2016-09-14 Συνθεση λιποσωματος

Country Status (33)

Country Link
US (3) US20120058178A1 (el)
EP (1) EP2415470B1 (el)
JP (1) JP5551683B2 (el)
KR (1) KR101495951B1 (el)
CN (1) CN102369008B (el)
AU (1) AU2010232347A1 (el)
BR (1) BRPI1014527B8 (el)
CA (1) CA2756811C (el)
CO (1) CO6430500A2 (el)
CY (1) CY1118231T1 (el)
DK (1) DK2415470T3 (el)
ES (1) ES2593027T3 (el)
HK (1) HK1165707A1 (el)
HR (1) HRP20161157T1 (el)
HU (1) HUE029577T2 (el)
IL (1) IL215059A (el)
LT (1) LT2415470T (el)
MA (1) MA33127B1 (el)
ME (1) ME02518B (el)
MX (1) MX2011009632A (el)
MY (1) MY160203A (el)
NZ (1) NZ595212A (el)
PE (2) PE20120923A1 (el)
PL (1) PL2415470T3 (el)
PT (1) PT2415470T (el)
RS (1) RS55148B1 (el)
SG (1) SG174255A1 (el)
SI (1) SI2415470T1 (el)
SM (1) SMT201600307B (el)
TW (1) TWI392519B (el)
UA (1) UA103794C2 (el)
WO (1) WO2010113984A1 (el)
ZA (1) ZA201106535B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
ES2593027T3 (es) 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
WO2010113983A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
WO2012119077A1 (en) 2011-03-02 2012-09-07 Morphotek Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer
SG10201706239VA (en) * 2013-02-01 2017-08-30 Zoneone Pharma Inc Remote loading of sparingly water-soluble drugs into liposomes
AU2015301234A1 (en) 2014-08-04 2017-06-15 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
HRP20211776T8 (hr) 2015-09-18 2022-03-18 Technische Universität München Ligandi za integrin alfavbeta6, njihova sinteza i upotreba
JP6564873B2 (ja) * 2015-11-02 2019-08-21 富士フイルム株式会社 リポソーム組成物およびその製造方法
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
KR20190122676A (ko) * 2017-01-18 2019-10-30 테마섹 라이프 사이언스 래보러토리 리미티드 유사분열기세포의 표적화를 증가시키는 고안정화된 리포좀
US11332498B2 (en) 2017-03-17 2022-05-17 Technische Universitat Munchen Ligands for integrin αVβ8, synthesis and uses thereof
CA3058127C (en) * 2017-03-31 2022-07-05 Fujifilm Corporation Liposome composition and pharmaceutical composition
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US20230201119A1 (en) * 2020-05-29 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Liposome containing ethylenediamine tetraacetic acid or salt thereof and eribulin or pharmaceutically acceptable salt thereof
CN115957351B (zh) * 2022-11-15 2023-06-27 中国人民解放军海军第九七一医院 一种碘海醇注射液及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
CA2161225C (en) 1993-04-22 2003-07-01 Sinil Kim Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
FR2736056B1 (fr) 1995-06-29 1997-08-08 Commissariat Energie Atomique Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises
US6051251A (en) 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
DE122011100031I1 (de) 1998-06-17 2011-12-15 Eisai R&D Man Co Ltd Makrocyclische analoga und verfahren zu ihrer verwendung und herstellung.
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
AU2002340669A1 (en) 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions with enhanced blood stability
ES2290333T3 (es) 2001-11-13 2008-02-16 Celator Pharmaceuticals, Inc. Composiciones de vehiculos lipidicos y metodos para la retencion mejorada de farmacos.
DE10255106A1 (de) 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
WO2004047800A2 (en) 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
JP5355842B2 (ja) * 2002-12-31 2013-11-27 ザイダス ビーエスヴィ ファーマ プライベート リミテッド 非ペギレート化長循環性リポソーム
WO2004089419A1 (ja) * 2003-04-04 2004-10-21 The University Of Tokyo 抗ｍｔ－ｍｍｐモノクローナル抗体含有脂質膜構造体
US6747011B1 (en) 2003-06-04 2004-06-08 A.P. Group, Inc. Antitumor drugs and methods
US20050129753A1 (en) 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
CA2553573A1 (en) 2004-01-29 2005-08-11 Eisai R & D Management Co., Ltd. Method for stabilizing macrolide compound
US8147867B2 (en) * 2004-05-03 2012-04-03 Hermes Biosciences, Inc. Liposomes useful for drug delivery
DE602005018043D1 (de) 2004-05-17 2010-01-14 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
CA3028453C (en) 2004-06-03 2021-07-27 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
AU2005291807B2 (en) 2004-10-06 2012-04-19 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20090196913A1 (en) 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
US20090196918A1 (en) 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
WO2010113983A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
ES2593027T3 (es) 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
WO2011094339A1 (en) 2010-01-26 2011-08-04 Eisai R&D Management Co., Ltd. Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
EP2693875A4 (en) 2011-04-08 2014-10-22 British Columbia Cancer Agency BISPHENOL COMPOUNDS AND METHODS OF USE
WO2013012891A1 (en) 2011-07-19 2013-01-24 Stc. Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
CN105338977B (zh) 2013-06-26 2018-10-16 卫材R&D管理有限公司 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
EP3046543A1 (en) 2013-09-18 2016-07-27 Stc.Unm Torroidal mesoporous silica nanoparticles (tmsnps) and related protocells
WO2015095784A1 (en) 2013-12-19 2015-06-25 Luminus Biosciences, Inc. Solid nanoparticle formulation of microtubule inhibitors with reduced ostwald ripening for oral administration
RU2016136504A (ru) 2014-03-03 2018-04-03 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ
EP3148336B1 (en) 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
CN105640935A (zh) 2014-11-12 2016-06-08 天津市汉康医药生物技术有限公司 供注射用甲磺酸艾日布林药物组合物

Also Published As

Publication number Publication date
US20210023004A1 (en) 2021-01-28
KR20110122219A (ko) 2011-11-09
PE20120923A1 (es) 2012-08-27
DK2415470T3 (en) 2016-09-19
SI2415470T1 (sl) 2016-12-30
HUE029577T2 (en) 2017-03-28
JPWO2010113984A1 (ja) 2012-10-11
US20140044777A1 (en) 2014-02-13
EP2415470A4 (en) 2012-11-28
EP2415470B1 (en) 2016-07-06
NZ595212A (en) 2014-02-28
JP5551683B2 (ja) 2014-07-16
UA103794C2 (en) 2013-11-25
ES2593027T3 (es) 2016-12-05
MA33127B1 (fr) 2012-03-01
ZA201106535B (en) 2012-05-30
TWI392519B (zh) 2013-04-11
CA2756811A1 (en) 2010-10-07
WO2010113984A1 (ja) 2010-10-07
SG174255A1 (en) 2011-10-28
HRP20161157T1 (hr) 2016-11-18
PT2415470T (pt) 2016-08-31
EP2415470A1 (en) 2012-02-08
MY160203A (en) 2017-02-28
CN102369008A (zh) 2012-03-07
RS55148B1 (sr) 2016-12-30
MX2011009632A (es) 2011-10-19
HK1165707A1 (zh) 2012-10-12
CA2756811C (en) 2014-09-23
CO6430500A2 (es) 2012-04-30
US20120058178A1 (en) 2012-03-08
TW201102110A (en) 2011-01-16
KR101495951B1 (ko) 2015-02-25
IL215059A (en) 2016-03-31
US11071713B2 (en) 2021-07-27
PL2415470T3 (pl) 2016-12-30
SMT201600307B (it) 2016-11-10
PE20151519A1 (es) 2015-10-28
ME02518B (me) 2017-02-20
AU2010232347A1 (en) 2011-09-29
LT2415470T (lt) 2016-10-10
IL215059A0 (en) 2011-11-30
CN102369008B (zh) 2014-10-29
BRPI1014527B8 (pt) 2021-05-25
BRPI1014527B1 (pt) 2020-11-24
BRPI1014527A2 (pt) 2016-04-05

Similar Documents

Publication Publication Date Title
CY1118231T1 (el) Συνθεση λιποσωματος
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
CY1117650T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1118307T1 (el) Συνθεσεις που περιλαμβανουν βουπρενορφινη (buprenorphine)
CY1118416T1 (el) Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1116645T1 (el) Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
EA201170227A1 (ru) Имидазолкарбоксамиды
CR11861A (es) Compuestos organicos
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CY1112558T1 (el) Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους
ECSP11011338A (es) Anticuerpos biespecíficos anti-her
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
CY1112095T1 (el) Υποκατεστημενα σπειροκυκλικα παραγωγα κυκλοεξανιου
CY1112595T1 (el) Αμιδοφαινοξυινδαζολια χρησιμα ως αναστολεις του c-met
ME01009B (me) Kristalni oblici dimetoksi docetaksela i postupak za njihovo dobijanje
EA201070256A1 (ru) Способ и промежуточные соединения для получения ингибиторов интегразы
EA201070786A1 (ru) Бензофуропиримидиноны
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
CR20140135A (es) Nuevos derivados de aril-quinolina
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие